British drugmaker AstraZeneca Plc <AZN.L> could resume trials for its experimental coronavirus vaccine next week, the Financial Times reported on Wednesday, citing people associated with the trials. (https://on.ft.com/3m4ytwt)
The London-listed firm had to pause global trials of its potential vaccine for COVID-19 after an unexplained illness in a participant, which sent its shares lower as the move was seen as dimming prospects for an early rollout.
AstraZeneca did not immediately respond to a Reuters request for comment.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Sriraj Kalluvila)
